Marker Therapeutics, Inc. (NASDAQ:MRKR) Sees Significant Drop in Short Interest

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 255,701 shares, a decrease of 17.4% from the January 15th total of 309,450 shares. Approximately 1.7% of the shares of the stock are sold short. Based on an average trading volume of 485,071 shares, the days-to-cover ratio is presently 0.5 days. Based on an average trading volume of 485,071 shares, the days-to-cover ratio is presently 0.5 days. Approximately 1.7% of the shares of the stock are sold short.

Institutional Investors Weigh In On Marker Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new position in shares of Marker Therapeutics in the second quarter valued at about $33,000. Two Sigma Investments LP purchased a new position in Marker Therapeutics during the 3rd quarter valued at about $33,000. Virtu Financial LLC bought a new position in Marker Therapeutics during the 3rd quarter valued at approximately $25,000. Boyer Financial Services Inc. purchased a new stake in Marker Therapeutics in the 4th quarter worth approximately $57,000. Finally, Geode Capital Management LLC lifted its holdings in Marker Therapeutics by 35.3% in the 4th quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock worth $194,000 after buying an additional 34,028 shares during the period. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on MRKR. UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. HC Wainwright initiated coverage on Marker Therapeutics in a research note on Monday, December 8th. They issued a “buy” rating and a $10.00 target price on the stock. Wall Street Zen upgraded Marker Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Marker Therapeutics in a report on Monday, December 22nd. Finally, Zacks Research lowered Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Marker Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $10.17.

Marker Therapeutics Stock Performance

MRKR stock traded up $0.05 during trading on Wednesday, hitting $1.50. 60,553 shares of the company traded hands, compared to its average volume of 454,830. The company has a 50-day moving average of $1.64 and a 200-day moving average of $1.26. The firm has a market capitalization of $25.01 million, a PE ratio of -1.22 and a beta of 1.44. Marker Therapeutics has a 1 year low of $0.81 and a 1 year high of $4.07.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.